washed with dry EtOH and Et₂O to give the pure hydrochloride (0.358 g, 70%) of the desired Schiff base.

All the other Schiff bases were similarly prepared and are recorded in Table I.

Acknowledgments.—The authors are greatly indebted to Dr. H. B. Wood, Chief, Drug Development Branch, Cancer Chemotherapy National Service Center for his cooperation and for making the screening data available and to Mr. M. T. Jaokar for microanalyses. They are grateful to Dr. N. K. Dutta, Director, Haffkine Institute, Bombay, for providing facilities to carry out the present work.

Synthesis of Dideoxyzearalanone and Hydroxyl Derivatives


DAVID B. R. JOHNSTON, CAROL A. SAWICKI, T. B. WINDHOLZ, and A. A. PATCHETT

Synthetic Chemical Department, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065

Received May 4, 1970

Syntheses are reported of 2,4-dideoxyzearalanone and each of the possible monophenolic derivatives of this compound. The preparation of 5-hydroxyzearalanone is also described. None of the new compounds exceeded the parent in respect to estrogenic activity.

The isolation of zearalenone (1) and a preliminary account of its marked uterotrophic activity and anabolic properties were reported by Stob and coworkers.¹ The structure of this fungal metabolite was deduced by chemical and spectroscopic means,² total syntheses of zearalenone have been announced³ and its absolute configuration has also been determined.⁴



We have synthesized a number of structural variants of zearalenone in a joint project conducted several years ago with a group similarly engaged in the laboratories of the Commercial Solvents Corporation. The purpose of the present report is to summarize our findings in respect to the effect of phenolic OH addition or removal on the biological activity of the parent compound. This study was undertaken in a systematic way since the structural relationships of zearalenone to a typical estrogen such as estrone (2) are not obvious by inspection of models of their formulae. We selected as our synthetic goals the parent 2,4-dideoxyzearalanone (6) and each of the possible monosubstituted phenolic analogs, as well as 5-hydroxyzearalanone.

Chemistry.—Hydrogenolysis of the phenolic hydroxyls in zearalenone was possible using the technique of Musliner and Gates.⁵ This involved preparation of


(2) W. H. Urry, H. L. Wehrmeister, E. B. Hodge, and P. 11. Hidy, Tetrahedron Lett., 3109 (1966).

(3) D. Taub, N. N. Girotra, R. D. Hoffsommer, C. H. Kuo, H. L. Slates, S. Weber, and N. L. Wendler, *Chem. Commun.*, 225 (1967); N. N. Girotra and N. L. Wendler, *Chem. Ind.* (London), 1493 (1967); D. Taub, N. N. Girotra, R. D. Hoffsommer, C. H. Kuo, H. L. Slates, S. Weber, and N. L. Wendler, *Tetrahedron*, 24, 2443 (1968); 1. Vlattas, 1. T. Harrison, L. Tokes, J. H. Fried, and A. D. Cross, J. Org. Chem., 33, 4176 (1968). Total synthesis of dideoxyzeralane was reported by H. L. Wehrmeister and D. E. Robertson, J. Org. Chem., 33, 4173 (1968).

(4) C. H. Kuo, D. Taub, R. D. Hoffsommer, N. L. Wendler, W. H. Urry, and G. Mullenbach, Chem. Commun., 761 (1967).


(5) W. J. Musliner and J. W. Gates, J. Amer. Chem. Soc., 88, 4271 (1966). See also H. L. Wehrmeister and D. E. Robertson, J. Org. Chem., 33, 4173 (1968). the 1-phenyl-5-tetrazolyl ethers and their hydrogenolysis with 5% Pd–C which concurrently caused reduction of the olefin functionality. Our preferred conditions were 95% EtOH as solvent, and 3.5 kg/cm^2 at about 70° for 48 hr. These conditions are more drastic than those which were of general utility for Musliner and Gates.

In order to attain selective removal of the 2- and 4-hydroxyls of zearalenone it was necessary to prepare the required monophenyltetrazolyl derivatives. This was accomplished from the 2-benzyl and 4-tetrahydropyranyl ethers whose preparation is shown in Scheme I.



The key reaction in this sequence was the selective monotetrahydropyranyl ether formation at C-4 in good yield using excess dihydropyran. This selectivity is attributed to the equilibrium nature of the reaction. Steric hindrance at C-2 and a loss of H bonding to the lactone CO are considered to disfavor derivatization of the 2-OH. It is also worth noting that benzyl ether formation is possible using K_2CO_3 in MeOH without any appreciable opening of the lactone ring. Formation of the phenyltetrazolyl ethers 5, 7, and 9 went well from the corresponding phenols using anhyd K_2CO_3 and 1-phenyl-5-chlorotetrazole in refluxing dry Me₂CO for 16 hr. The properties of these derivatives and of their


⁽¹⁾ M. Stob, R. S. Baldwin, J. Tuite, F. N. Andrews, and K. G. Gillette, Nature (London), 196, 1318 (1962).



corresponding hydrogenolysis products are summarized in Table I.

The preparation of analogs monosubstituted with OH at C-3 and C-5 was accomplished from the dideoxy derivative 6 as summarized in Scheme II. As antici-

Зснеме П



pated, nitration of **6** went primarily para to the alkyl group and to a lesser extent ortho to that function. Reduction of the pure $3\text{-}NO_2$ analog (11) with 5%Pd-C and diazotization of the amine 12 led to the C-3 monohydroxy analog 13. The C-5 monohydroxy analog 14 was obtained from a similar sequence using a mother liquor fraction containing the 5-NO₂ analog.

5-Hydroxyzearalanone (18) was obtained via an aminozearalanone first prepared by E. B. Hodge of the Commercial Solvents Corp. and assigned by him structure 15 from physical data. Oxidation of 15 with Ag₂O-NH₄OH gave, after acidification, hydroxyquinone 16 best isolated as the acetate 17, thereby providing chemical support for the assigned structure 15. By shaking the Et₂O extract of 16 with aq Na₂S₂O₄, 18 was obtained directly. These conversions are summarized in Scheme III.

Biological Evaluation.—Estrogenic activities were estimated for the zearalenone analogs prepared in this study by a determination of their oral uterotrophic properties in rats using diethyl stilbestrol as the standard.⁶ In this assay zearalenone (1) and its $C_1'-C_2'$ dihydro derivative zearalanone show about 0.1%the activity of the standard. The dideoxy derivative **6** has less than 0.1 of the activity of zearalanone. 2-De-

(6) R. I. Dorfman and A. S. Dorfman, Endocriaology, 55, 65 (1954).

oxyzearalanone (8) retained about two-thirds of the activity of zearalanone (1); however, the other monohydroxy analogs showed less than 0.1 of the activity of zearalanone, while 5-hydroxyzearalanone had less than one-third of the estrogenic activity of the parent diol. Introduction of a third OH at either C-2⁷ or C-4⁸ in estradiol, leads to a sharp decrease in estrogenicity. Introduction of a third OH at C-19 in estradiol also causes a sharp drop in estrogenicity, unlike our finding that zearalanone is more active than the 2-deoxy derivative. We interpret the activating effect of the 2-OH in zearalanone to be the result of a conformational restriction which H bonding of the lactone imposes on the molecule.¹⁰ We believe that the 4-OH of zearalanoue corresponds to the 3-OH of estradiol in respect to its effect on intrinsic estrogenic activity.

Experimental Section¹¹

6-(10-Hydroxy-6-oxo-brans-1-undecenyl)- β -resorcylic Acid μ -Lactone 4-(2-Tetrahydropyranyl) Ether (3) .--- A suspension of 8.0 g (25.6 mmoles) of 1 in 8 ml of dihydropyrau and 4 drops of concd HCl was stirred at room temperature for 4 hr, an additional 8 ml of dihydropyran was then added, and the suspension was stirred overnight. The resultant solution was poured into saturated aq NaHCO₃ and extracted with EtOAc. The extract was washed with dil NaOH, H₂O, and NaCl solution, dried, and evaporated under reduced pressure. The 8.8 g of residue was dissolved in 450 ml of MeOH and cooled to 0°; 3.76 g of 3 was obtained, mp 146-149°. A second crop was obtained after concentration to ca. 150 ml, giving 4.20 g of 3, mp 114-115°. Both of these fractions were 4-THP derivatives as judged by their spectra and both were snitable for further transformations. Repeated crystallization from MeOH of a portion of the first crop gave an analytical sample which melted at 159-160°. Anal. (C H₃₀O₆) C, H.

6-(10-Hydroxy-6-oxo-*trans***-1-undeceny**])- β -resorcyclic Acid μ -Lactone 2-Benzyl Ether (4). — A mixture of 500 mg (1.24 mmoles) of tetrahydropyranyl ether 3, 400 mg (2.92 mmoles) of anhyd K₂CO₃, 0.42 ml (3.68 mmoles) of PhCH₂Cl, and 12.5 ml of anhyd MeOH was refluxed under N₂ for 16 hr, cooled, and filtered. The filtrate was discarded and the filter cake was washed repeatedly with CHCl₃. Evaporation of the washes yielded 535 mg of material which was crystallized from 45 ml of hot MeOH to give 300 mg (48%) of 4 as its 4-tetrahydropyranyl ether.


A solution of 250 mg (0.51 mmole) of this 4-tetrahydropyrapyl ether in 50 ml of dioxane with 0.25 ml of 2.5 N HCl was heated

(7) S. Gordon, E. W. Cantrall, W. P. Cekleniak, H. J. Albers, S. Maner, S. M. Stolar, and S. Bernstein, *Steroids*, 4, 267 (1964).

- (8) C. Huggins and E. V. Jensen, J. Exp. Med., 102, 335 (1955).
- (9) E. Hecker and G. Farthofer-Boeckli, *Biochem. Z.*, **338**, 628 (1963).

(10) Several other effects of conformational change on the chemistry and physical properties of zearalenone and its derivatives will be discussed in subsequent publications.

(11) Melting points were determined using a Koffler melting point apparatus and are uncorrected. Where analyses are indicated only by symbols of the elements, analytical results are within $\pm 0.4\%$ of the theoretical values. Nur, (iv. and ir data were in all cases consistent with the structures proposed.



on the steam bath for 15 min, then poured onto ice. The aq suspension was extracted into EtOAc, washed, dried, and evaporated to yield 172 mg (81%) of 4, suitable for further chemical transformations. Recrystallization from CH₂Cl₂-Et₂O gave an analytical sample, mp 165-167°. Anal. (C₂₅H₂₈O₅) C, H.

6-(10-Hydroxy-6-oxo-trans-1-undecenyl)- β -resorcyclic Acid μ -Lactone 2,4-Bis(1-phenyl-5-tetrazolyl) Ether (5). General Procedure for Tetrazolyl Ether Formation.—A mixture of 2.0 g (6 mmoles) of 1, 2.17 g (12 mmoles) of 1-phenyl-5-chlorotetrazole, 2.4 g (24 mmoles) of anhyd K₂CO₃, and 18 ml of dry Me₂CO was stirred and refluxed under N₂ for 16 hr and filtered. The filtrate was evaporated under reduced pressure, the residue was swirled with C₆H₆ and taken to dryness under reduced pressure. Finally, the residue was dissolved in CH₂Cl₂ and concentrated to an oil. Addition of MeOH afforded 3.35 g (92%) of white crystals of 5. Recrystallization from MeOH afforded the analytical sample of mp 166–168°. Anal. (C₂₂H₃₀N₅O₆) C, H, N.

2-(10-Hydroxy-6-oxoundecyl) benzoic Acid μ -Lactone (6). **Hydrogenolysis Procedure.**—A mixture of 2.5 g (4.12 mmoles) of bisphenyltetrazolyl ether (5), 0.5 g of 5% Pd–C, and 640 ml of 95% EtOH was shaken for 48 hr at 70° under H₂ at 3.5 kg/cm² and filtered and the filtrate evaporated under reduced pressure to afford 3.1 g of crude product. This was extracted with 25 ml of hot Et₂O and filtered quickly. A noncrystalline precipitate which formed in the solution at room temperature was filtered off. Further cooling and scratching of the Et₂O solution afforded a dense fibrous mass of crystalline **6**. Further recrystallizations (Et₂O) provided an analytical sample, mp 89–91°. Anal. (C₁₃H₂₄O₃) C, H.

Compounds 8 and 9 whose properties are described in Table I were prepared by the same hydrogenolysis conditions. However, it was necessary to resort to column chromatography to separate the products from phenyltetrazolone or to wash the latter out with dilute base. It is noteworthy that the THP group in 7 was usually cleaved during the hydrogenolysis so that 8 was obtained directly.

2-(10-Hydroxy-6-oxoundecyl)-5-nitrobenzoic Acid μ -Lactone (11).—To 5.0 ml of fuming HNO₃, cooled with ice to 3°, was added 2.0 g (6.93 mmoles) of dideoxy compound **6** in portions over a 15-min period with cooling and vigorous stirring. After an additional 30 min the solution was poured into about 70 ml of ice and H₂O. The resultant gum was taken up with EtOAc and this solution was washed with aq NaHCO₃, dried, and taken to dryness under reduced pressure. Crystallization (Et₂O) gave 0.632 g of 11 (27%). The analytical sample from Et₂O had mp 108–110°. Anal. (C₁₈H₂₃NO₅) C, H, N.

2-(10-Hydroxy-6-oxoundecyl)-5-aminobenzoic Acid μ -Lactone (12).—A mixture of 2.5 g (7.5 mmoles) of nitro compound 11, 0.25 g of 5% Pd-C, and 250 ml of MeOH was shaken with H₂ at atmospheric pressure until 3 equiv had been absorbed. Filtration and evaporation of the filtrate under reduced pressure gave 2.18 g of white solid which was crystallized from MeOH in 5 crops to yield 1.74 g (76%) of 12. An analytical sample was prepared from the same solvent, mp 139–140°. Anal. (C₁₅H₂₅NO₈) C, H, N.

2-(10-Hydroxy-6-oxoundecyl)-5-hydroxybenzoic Acid μ -Lactone (13).—A mixture of 4.05 g (13.4 mmoles) of amine 12, 36.9 ml of H₂(), and 28.7 ml of concd H₂SO₄ was stirred vigorously

giving an almost complete solution. Addition of 60-70 g of ice and vigorous stirring with ice bath cooling afforded a fine suspen-To this was added a solution of 0.943 g (15.5 mmoles) of sion. NaNO2 in 20.5 ml of H2O. Stirring was continued for 20 min and then the solution was decanted from some undissolved material and decomposed by immersion in an oil bath preheated to 130° where it was allowed to reflux for 30 min. During this time the solution clouded, turned orange, and then lightened as a brown oil separated. The mixture was poured into cold H₂O, extracted with EtOAc and this solution after washing and drying was concentrated under reduced pressure to yield 3.4 g of a foam. Crystallization from CH₂Cl₂-Et₂O gave in 4 crops, 1.48 g (36%) of 13. The analytical sample from the same solvent had mp 130-133°. Anal. $(C_{18}H_{24}O_4) C, H.$

2-(10-Hydroxy-6-oxoundecyl)-5-hydroxybenzoic Acid μ -Lactone (14).—Mother liquors from a large preparation of 5-NO₂ analog 11 on further crystallization from Et₂O gave a small fraction, mp 88-89° which according to gle was a 1:1 mixture of 11 and another compound; analytical data suggested it was a mixure of mononitro derivatives.

This fraction of mp 88-89° (2.0 g, 6.0 mmoles) was reduced in 200 ml of MeOH using 5% Pd-C and H₂ at atmospheric pressure. After 3 equiv of H₂ had been absorbed, the solution was filtered and concentrated. Treatment of the crude amine mixture under the same diazotization conditions used in preparing 13 from 12 afforded 1.27 g of foam. Peparative tlc on silica gel using 20% Et₂O in CH₂Cl₂ afforded 14. Recrystallization from CH₂Cl₂-Et₂O provided the analytical sample, mp 124-127°. Anal. (C₁₈H₂₄O₄) C, H.

5-Acetoxy-3-(10-hydroxy-6-oxoundecyl)benzoquinone-2-carboxylic Acid μ -Lactone (17).—A solution of Ag₂O, from 0.5 g AgNO₃, in 5 ml of concentrated NH₄OH, was added dropwise over 1 min with stirring to a solution of 0.5 g (1.5 mmoles) of 15 in 5 ml of concentrated NH4OH at 0°. After stirring for another 5 min, the reaction mixture was centrifuged and the blood red supernatant liquid added to a vigorously stirred ice-cold mixture of Et2O and dil H2SO4. The phases were separated and the strongly acidic aq phase was extracted 2-3 more times with Upon combination of the extracts, washing with saturated Et₂O. aq NaCl, drying, and careful evaporation, a yellow gum was obtained which partially crystallized on standing. Careful titration with EtO_2 permitted isolation of the quinone 16 which could be recrystallized from MeOH. Isolation of the quinone was preferably carried out in the form of the acetate. Thus the gum was treated with 1.0 ml of Ac₂O and a trace of pyridine. After 5-10 min at room temperature, the volatile materials were removed with a gentle N₂ stream to give a crystalline residue. Recrystallization from MeOH or *i*-PrOH gave the quinone acetate 17 as bright yellow needles, mp $133-136^{\circ}$. Anal. (C₂₀H₂₄O₇) C, H.

5-Hydroxy-6-(10-hydroxy-6-oxoundecyl)- β -resorcyclic Acid μ -Lactone (18).—The Et₂O extract obtained in the preparation of 16 was shaken with 1 g of Na₂S₂O₄·2H₂O (per 0.5 g of starting 15) in 50-100 ml of H₂O. The resultant off-color organic phase was then washed with saturated aq NaCl, dried, and evaporated under reduced pressure to give 0.3-0.4 g of solid. Recrystallization from EtOH gave pure triol 18, mp 210-215° dec. Anal. (C₁₈-H₂₄O₈) C, H. Acknowledgments.—The authors are indebted to Dr. Stanford L. Steelman, Dr. Dolores Patanelli, Dr. J. Brooks, and their coworkers for the endocrine data. Zearalenone was provided for these studies by the Commercial Solvents Corporation through arrangements made by Mr. M. Bachman. The authors also express their appreciation to Dr. W. Jones and his associates for the hydrogenations, to Mr. R. N. Boos and his associates for the microanalyses, and to Dr. B. Arison and coworkers for determination of the nmr spectra.

Relationship between Lipophilic Character and Hemolytic Activity of Testosterone and Testosterone Esters

Gian Luigi Biagi, Maria Clelia Guerra, and Anna Maria Barbaro

Istituto di Farmacologia e Farmacognosia, Università di Bologna, Bologna, Italy

Received February 15, 1970

The relationship between lipophilic character and hemolytic activity was studied in a series of testosterome compounds. The lipophilic character was first expressed by means of the chromatographic R_{10} value, which was shown to be related to the partition coefficient between the mobile and the stationary phase of a chromatographic system. The R_m value was determined, for each compound, in two different chromatographic systems, respectively, containing in the mobile phase Me₂CO or MeOH. In both cases there was a highly significant parabolic relationship between R_m values and hemolytic activity. On the other hand this result could be expected from the linear relationship between the R_m values, respectively, determined with Me₂CO or MeOH in the mobile phase. The lipophilic character of the test compounds was also expressed by means of the π values. There was a linear relationship between the π values calculated from octanol-H₂O partition coefficients and the chromatographic R_{10} values. A parabolic relationship was therefore shown also between π values and hemolytic activity. The present results support previous findings, which suggest that the correlation between penetration of organic compounds through biological membranes and partition coefficient is not affected by the nature of the phases involved in the determination of the partition data.

The hemolytic activity of some neutral steroids was shown by Tateno and Kilbourne¹ and Palmer.² Weissmann and Keiser³ in a series of 35 neutral steroids and bile acids pointed out that while the 5- β -H configuration was associated with hemolytic properties, the $5-\alpha$ -H compounds were inactive and only a few Δ -4,5 steroids were active. Testosterone, which is a Δ -4,5 steroid, was found practically inactive,^{1,3} while Palmer² observed some activity. Segaloff⁴ described the hemolytic activity in vitro and in vivo of some testosterone esters. The hemolytic activity was interpreted as a consequence of the insertion of the steroids at the lipidaqueous interface at the surface of the erythrocyte.^{3,5} On the other hand, no direct relationship was found between hemolytic activity and water solubility.³ However the acetate derivatives were found to be more active than their parent compounds.³ An enhanced hemolytic activity was also found in the AcOH and BzOH esters of some steroidal sapogenins.⁶ This could suggest the influence of the lipophilic character of the molecules, at least in a series of ester derivatives. Hansch, *et al.*,⁷ found very good correlations between partition coefficient and penetration of organic compounds through biological membranes. In previous papers it was possible to show that reversed-phase tlc is a suitable method for the determination of the lipophilic character of drugs, as expressed by the $R_{\rm m}$ value.⁸

(8) (a) G. L. Biagi, A. M. Barbaro, M. F. Gamba, and M. C. Guerra, J. Chromatogr., 41, 371 (1969); (b) G. L. Biagi, A. M. Barbaro, M. F. Gamba, and M. C. Guerra, *ibid.*, 44, 195 (1969). Therefore, the main purpose of the present work was to study the relationship between $R_{\rm m}$ values and hemolytic activity of a series of testosterone esters, also, to study the influence, on the above relationship, of the phase system used for determining the lipophilic character.

Materials and Methods

The testosterone compounds were kindly provided by drug companies (Organon N.V., Vister Vismara Terapeutici S.p.A., Istituto Luso Farmaco d'Italia s.r.1., Armour Erba Farmaceutici S.p.A, Essex Italia S.p.A.) and obtained from commercial sources (Prodotti Gianni, Milan). Their structures are reported in Table I. The chromatographic procedure for the determination of the R_{ni} values was also used in order to check the purity of the compounds.

 $R_{\rm m}$ Values Determination.---The lipophilic character of the test compounds was expressed by their chromatographic $R_{\rm m}$ values, which have previously been described.⁸ The stationary nonpolar phase consisted of a silica gel G layer impregnated with silicone DC 200 (350 cSt) from Applied Sciences Laboratories. The impregnation was carried out by developing the plates in a 5% silicone oil solution in Et₂O. The polar mobile phase, saturated with silicone oil, was represented by H_2O in various mixture (v/v) with Me_2CO or MeOH. In particular the concentration of Me₂CO ranged from 42 to 74%, that of MeOH, from 54 to 86%. Two plates were simultaneously developed in a chromatographic chamber containing 200 ml of mobile phase. The steroids were dissolved in Me₂CO (3 mg/ml) and 1 μ l of solution was spotted randomly on the plates in order to avoid any systematic error. The developed plates were dried and sprayed with an alkaline solution of $KMnO_4$. After a few minutes at 120° yellow spots appeared on an intensely pink background. The $R_{\rm m}$ values were calculated by means of the formula:

^{(1) 1.} Tateno and E. D. Kilbourne, Proc. Soc. Exp. Biol., 86, 168 (1954).

⁽²⁾ R. H. Palmer, Nature (London), 201, 1135 (1964).

⁽³⁾ G. Weissmann and H. Keiser, Biochem. Philimacol., 14, 525 (1965).

⁽⁴⁾ A. Segaloff, J. Clin. Endocrinol, Metabol., 14, 244 (1954)

⁽⁵⁾ J. T. Dingle, "Lysosomes," A. V. S. de Reuck and M. D. Cameron Ed., Churchill, London (1963).

⁽⁶⁾ R. Segal, M. Mansour, and D. V. Zaitschek, Biochem. Pharmacol., 15, 1411 (1966).

^{(7) (}a) C. Hansch, A. R. Stewart, J. Iwasa, and E. W. Deutsch, Mol. Pharmacol., 1, 205 (1965); (b) J. T. Penniston, L. Beckett, D. L. Bentley, and C. Hansch, *ibid.*, 5, 333 (1969).